WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

https://www.devdiscourse.com/article/business/1614833-china-stocks-fall-as-sino-west-tensions-hit-risk-appetite ... Shanghai shares of WuXi AppTec Co Ltd, one of the heavyweight stocks in the healthcare sub-index, fell 4.8% by the mid-day break after falling as much as 6.3%. ** Stocks slumped after WuXi received a regulatory letter from the Shanghai Stock Exchange, as one of its shareholders cut stakes without proper information disclosure.  ...

Hong Kong stocks move | WuXi AppTec (02359) AH shares fell nearly 6%, recently shareholders violated their promises to reduce their holdings by about 2.894 billion yuan https://finance.sina.cn/hkstock/sckxjfx/2021-06-16/detail-ikqciyzi9897375.d.html?from=wap WuXi AppTec (02359) AH shares fell sharply in early trading, and A shares fell more than 6% in intraday trading. As of press time, H shares fell 5.54% to 158.5 Hong Kong dollars, with a turnover of 83,886,600 Hong Kong dollars. On the news, WuXi AppTec recently disclosed the "Announcement on Shareholders’ Violation of Commitments to Reduce Shares in the Company and Approval of the Company’s Apology", stating that the company’s shareholder Shanghai Yingyi was held from May 14 to June 8 this year. The center has reduced its holdings of approximately 17,249,700 shares, accounting for 0.6962% of the company's total share capital. The price range of the reduction is RMB 143.49 per share to RMB 176.88 per share, and the total amount of reduction is 2.894 billion yuan. Violation of its relevant commitment to reduce the company's shares at the time of the IPO. WuXi AppTec received a supervisory work letter from the Shanghai Stock Exchange due to shareholders' illegal reduction of holdings, requesting shareholders to formulate necessary and sufficient compensation measures as soon as possible to effectively protect the legitimate rights and interests of investors.

Ich hatte Freitag und heute mal bei Trade_Republic geschaut und kurz vor 8 Uhr lag der spread bei 1,x %, pünktlich ab 8 Uhr deutlich höher (5,x % und höher). Hatte es aber nur getestet und keinen Kauf ausgeführt.

Montag müsste die Börse in HK geschlossen sein.

Ja, ist schon heftig und war mir gar nicht so bewusst. Die WuXi Bio ist da wahrscheinlich die beliebtere von den beiden. Ich muss auch gestehen, dass ich bisher öfter die WuXi Bio aufgestockt habe und die AppTec etwas stiefmütterlicher behandele 🙃. Missen möchte ich die AppTec aber auch nicht.

Das kann sich eigentlich nur durch mehr Liquidität und mehr handeln ändern

Bei einer Aktie, die 18 € kostet

Also über 1 € Spread ist schon fies

Habe es nicht beobachtet bzw drauf geachtet. Hast du es mal zwischen 9 und 10 Uhr getestet? Dann ist hier 'normale' Handelszeit und Hongkong auch noch geöffnet. Vielleicht einen Versuch wert.

gibt es eine Zeit in der der Spread mal nicht allzu hoch ist? Hast du das mal beobachtet

Na dann kann es ja weiter gehen.

WuXi AppTec (02359) issued 427 million A shares and 63.155 million H shares based on the capitalization of capital reserves https://finance.sina.cn/hkstock/gsxw/2021-06-08/detail-ikqcfnaz9881172.d.html?from=wap WuXi AppTec  (02359) issued an announcement to issue 427 million A shares and 63.155 million H shares for the issuance of 2020 capitalized shares based on the conversion of capital reserves in 2020 to take effect on June 8, 2021. In addition, based on the conversion and issuance of 58,900 H shares based on the $300 million zero coupon convertible bonds maturing in 2024, the issue price per share is HK$79.85, a 52.58% discount to the closing price of HK$168.4 per share on June 7.

Jepp

Die Stockdividende ist schon mal angekommen.

Morgan Stanley: To WuXi AppTec (02359) "overweight" rating target price raised to 198 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/05/25103732815475.shtml Zhitong Finance APP learned that Morgan Stanley released a research report and assigned WuXi AppTec (02359) an "overweight" rating, and the target price was raised from 187 Hong Kong dollars to 198 Hong Kong dollars. According to the report, the company's performance in the first quarter was better than expected, and the mainland market's revenue growth rate was relatively high. The bank accordingly raised its 2021-24 profit forecast by 1% to 3%, considering the industry prospects attractive. Based on past performance, the market expects that once the company's products are approved, it will generate zero-cost licensing fee income, and the core business fundamentals are also stable, so there is a certain premium.